Form 4: Amylyx Pharmaceuticals Director, Karen Firestone, Reports Stock Option Grant

Karen Firestone, a director at Amylyx Pharmaceuticals, reported the acquisition of a stock option to purchase 25,000 shares of common stock.

Summary

• On June 6, 2024, Karen Firestone, a director of Amylyx Pharmaceuticals, Inc., was granted a stock option to purchase 25,000 shares of the company's common stock at an exercise price of $1.76.
• The option vests fully on the earlier of June 6, 2025, or the date of the next annual meeting, contingent upon continuous service to the issuer through the vesting date.
• Following the transaction, Firestone directly owns derivative securities consisting of 25,000 stock options.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing related to stock option grants. It is neutral in tone and doesn't inherently indicate positive or negative sentiment. The grant itself can be seen as a positive incentive for the director.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock options are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.

Key Dates